Purdue CEO: The Year For Transformative M&A Is Here
This article was originally published in The Pink Sheet Daily
The private specialty pharma is shopping for a transformative deal or a series of smaller deals that will diversify the company into a new area outside of pain and CNS disorders, CEO Mark Timney says during interview.
You may also be interested in...
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.
The private pain specialist is interested in business development opportunities in its core therapeutic space and adjacencies, but also looking at other ‘innovative’ technologies and partnerships with ex-US drug manufacturers, CEO Timney said during an interview.
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.